Hyperoside attenuates OVA-induced allergic airway inflammation by activating Nrf2

Area of Science:

• Immunology
• Pharmacology
• Respiratory Medicine

Background:

• Allergic airways disease (AAD) involves significant allergic airway inflammation.
• Hyperoside, from Rhododendron brachycarpum, exhibits known anti-inflammatory properties.

Purpose of the Study:

• To investigate the protective effects of hyperoside against ovalbumin (OVA)-induced allergic airway inflammation in a mouse model.
• To elucidate the molecular mechanisms underlying hyperoside's anti-inflammatory action.

Main Methods:

• An OVA-induced asthma model was established in mice, with hyperoside administered prior to OVA challenge.
• Key inflammatory markers (IL-4, IL-5, IL-13, IgE) and oxidative stress indicators (MDA, GSH, SOD) were quantified.
• Lung histopathology, airway hyperresponsiveness (AHR), NF-κB activation, and Nrf2/HO-1 pathway expression were analyzed.

Main Results:

• Hyperoside significantly reduced inflammatory cell infiltration and levels of IL-4, IL-5, IL-13, and IgE.
• It mitigated OVA-induced oxidative stress and inhibited airway hyperresponsiveness.
• Hyperoside suppressed NF-κB activation and activated the Nrf2/HO-1 signaling pathway.

Conclusions:

• Hyperoside demonstrates significant therapeutic potential in ameliorating allergic airway inflammation.
• The anti-inflammatory effects are mediated through the activation of the Nrf2 signaling pathway.
• Hyperoside offers a promising natural compound for managing allergic airways disease.